FDA has granted approval to Zydus Lifesciences under ANDA 218361, paving the way for the manufacturer to potentially enter a new market segment and challenge competitors with the launch of this product. This regulatory milestone underscores the company's growth within the generics space and is expected to positively impact its competitive positioning and revenue outlook.